Zocor Indications/Uses

REDUCTIONS IN RISK OF CHD MORTALITY AND CARDIOVASCULAR EVENTS: In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, ZOCOR is indicated to: Reduce the risk of total mortality by reducing CHD deaths; Reduce the risk of non-fatal myocardial infarction and stroke; Reduce the need for coronary and non-coronary revascularization procedures.
HYPERLIPIDEMIA: ZOCOR is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia, heterozygous familial hypercholesterolemia or combined (mixed) hyperlipidemia when response to diet and other nonpharmacological measures is inadequate. ZOCOR therefore, lowers the LDL-C/HDL-C and the total-C/HDL-C ratios.
PEDIATRIC PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: ZOCOR is indicated as an adjunct to diet to reduce total-C, LDL-C, TG, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolemia (HeFH).
GENERAL RECOMMENDATIONS: Prior to initiating therapy with ZOCOR, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.